Friday, August 14, 2015
Covance Drug Development has relocated its clinical research unit (CRU) in Dallas to a new, fit-for-purpose clinical research facility. The new unit, which opened earlier this month, has expanded from 72 to 100 medical beds and is located in the same building as the prior unit. In addition, a LabCorp patient service center will be co-located in the CRU, at which patients will have an opportunity to learn more about volunteering and participating in early-stage clinical trials.
Epic Sciences, a San Diego, Calif.-based developer of novel diagnostics to personalize and advance the treatment and management of cancer, has inked an agreement with Laboratory Corporation of America Holdings (LabCorp), a Burlington, N.C.-based healthcare diagnostics company, to provide circulating tumor cell (CTC) technology and support oncology clinical trials in Asia through Covance Drug Development.
The Society for Clinical Research Sites (SCRS), a global trade organization dedicated to representing the interests of clinical research sites, has announced a two-year partnership with Laboratory Corporation of America Holdings (LabCorp). Covance Drug Development will participate as a Global Impact Partner (GIP), a relationship designed to facilitate critical dialogue between industry stakeholders and clinical research sites.
Barely two months after LabCorp finalized its acquisition of Covance, Quintiles has signed a broad agreement with Quest Diagnostics to form a joint venture creating one of the world’s largest central laboratory services companies. The two high-profile central lab-CRO combinations raise the question of whether more such mergers and partnerships will follow.
LabCorp, a North Carolina-based healthcare diagnostics company, and Shandong XuanZhu Pharma, the wholly-owned subsidiary for innovative drug R&D of Sihuan Pharmaceutical, have inked a long-term partnership with Covance Drug Development (part of LabCorp) to support the global development of Sihuan’s drug candidate pipeline.
Contract research organizations (CROs) have become more effective in managing working relationships with investigative sites during the past two years, according to a new CenterWatch survey, yet the average CRO continues to fall below performance expectations in many of the areas investigators consider most critical for study success.